TGFB2 gene

Last updated on: 08.06.2024

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The TGFB2 gene (TGFB2 stands for: Transforming Growth Factor Beta 2) is a protein-coding gene located on chromosome 1q41. The TGFB2 gene encodes several isoforms that may be subject to similar proteolytic processing. The TGFB2 gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors, which leads to the recruitment and activation of transcription factors of the SMAD family that regulate gene expression. An important paralog of this gene is TGFB3.

General informationThis section has been translated automatically.

The encoded preprotein is proteolytically processed to generate a latency-associated peptide (LAP) and a mature peptide, and is present either in a latent form consisting of a mature peptide homodimer, an LAP homodimer and a latent TGF-beta binding protein, or in an active form consisting only of the mature peptide homodimer. The mature peptide can also form heterodimers with other members of the TGF-beta family.

TGF2 is a multifunctional protein that regulates various processes such as angiogenesis and heart development. After cleavage of the proprotein in the Golgi apparatus, the chains of the latency-associated peptide (LAP) and the transforming growth factor beta-2 (TGF-beta-2) remain non-covalently linked, which means that TGF-beta-2 remains inactive during storage in the extracellular matrix. At the same time, the LAP chain interacts with "milieu molecules" such as LTBP1 and LRRC32/GARP, which control the activation of TGF-beta-2 and keep it in a latent state during storage in extracellular milieus. Once TGF-beta-2 is activated after the release of LAP, it acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transmit the signal.

Clinical pictureThis section has been translated automatically.

Diseases associated with TGFB2 include:

LiteratureThis section has been translated automatically.

  1. DiLorenzo MP et al. (2023) Myocardial Fibrosis in Congenital Heart Disease and the Role of MRI. Radiol Cardiothorac Imaging 5:e220255.
  2. Karur GR et al. (2018) Diffuse Myocardial Fibrosis in Children and Adolescents With Marfan Syndrome and Loeys-Dietz Syndrome. J Am Coll Cardiol 72:2279-2281.
  3. Messer N et al. (2024) Outcomes of complex abdominal wall reconstruction in patients with connective tissue disorders: a single center experience. Hernia. DOI: 10.1007/s10029-023-02957-y
  4. Velchev JD et al (2021) Loeys-Dietz syndrome. Adv Exp Med Biol 1348:251-264.
  5. Yap WF et al. (2020) Co-existence of Marfan syndrome and systemic sclerosis: A case report and a hypothesis suggesting a common link. Int J Rheum Dis 23:1568-1573.

Last updated on: 08.06.2024